Preclinically, M7824 efficiently binds PD-L1 and TGF-β in vivo and suppressed tumor growth and metastasis more effectively than treatment with either an anti-PD-L1 antibody or TGF-β trap alone in syngeneic mouse models. Here, TGFB1 is linked to neoplasm.